checkAd

    wer kennt LUMINEX ??? - 500 Beiträge pro Seite

    eröffnet am 16.07.00 11:34:01 von
    neuester Beitrag 01.04.02 23:46:31 von
    Beiträge: 9
    ID: 186.577
    Aufrufe heute: 0
    Gesamt: 510
    Aktive User: 0

    ISIN: US55027E1029 · WKN: 936597
    31,42
     
    EUR
    +0,74 %
    +0,23 EUR
    Letzter Kurs 14.07.21 Tradegate

    Werte aus der Branche Pharmaindustrie

    WertpapierKursPerf. %
    1,0700+75,41
    1,4900+73,46
    0,7500+50,00
    1,5400+33,91
    0,7630+26,53
    WertpapierKursPerf. %
    5,0101-15,80
    3,8500-16,12
    7,5000-16,67
    1,8500-20,94
    3,6400-38,62

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 16.07.00 11:34:01
      Beitrag Nr. 1 ()
      wer kennt LUMINEX(936597)???seht euch mal den chart an.wer hat infos?
      gute geschäfte
      thebull 2
      Avatar
      schrieb am 17.07.00 22:02:12
      Beitrag Nr. 2 ()
      für alle interessierten.
      http://www.luminexcorp.com/products/
      sehr interesesant meiner meinung nach.
      gute geschäfte
      thebull 2
      Avatar
      schrieb am 02.05.01 22:53:26
      Beitrag Nr. 3 ()
      Luminex macht gerade eine nette Bodenbildung ,ich denke der Ausbruch
      steht unmittelbar bevor. (60 min stochastik,...)


      sind übrigens kein Zockerwert,sondern gehören mit, nach dem absturz ,immer noch über 400Mill.$ Marktcap.
      zu den großen im Bio EMERGING TECHNOLOGIES BEREICH (mit Affymetrix ,Caliper, Lion Bioscience,packard Bioscience)
      Ipo war am 30.3 2000
      Absturz war weil der Umsatz fürs erste q von 4.2 auf 3.9Mill revidiert wurde.
      Ist aber sicher im Kurs und die Aussichten sind weiter positiv
      Avatar
      schrieb am 24.05.01 21:45:41
      Beitrag Nr. 4 ()
      @thebull2
      alle achtung,dein letztes posting vom 2.5. - man beachte den zeitpunkt..... gut ! :cool:
      Avatar
      schrieb am 27.05.01 09:18:07
      Beitrag Nr. 5 ()
      moin berniek
      sorry,aber ich weiss nicht was du meinst.
      gruss
      tb 2

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 28.05.01 21:51:39
      Beitrag Nr. 6 ()
      ganz einfach, von nun an gings `berg auf`............... ;)
      Avatar
      schrieb am 28.05.01 23:09:26
      Beitrag Nr. 7 ()
      @berniek
      sorry aber ich kann dir immer noch nicht folgen.
      was hab ich denn am 2.5.gepostet???
      kann es sein das du mich mit 4now verwechselst?
      gruss
      tb 2
      Avatar
      schrieb am 23.08.01 13:36:19
      Beitrag Nr. 8 ()
      Thursday August 23, 7:31 am Eastern Time

      Press Release

      SOURCE: Luminex Corporation

      Luminex and Hitachi Software Announce Distribution and Agency Agreement
      For Japan

      - MiraiBio, Hitachi Software Engineering, and DNA Chip Research Sign On As Luminex`s Sole
      Japan-Based Agents -

      AUSTIN, Texas, ALAMEDA, Calif. and YOKOHAMA, Japan, Aug. 23 /PRNewswire/ -- Luminex Corporation (Nasdaq:
      LMNX - news) and MiraiBio, Inc.(MBI), a subsidiary of Hitachi Software Engineering, Co., Ltd.(HSW), announced today that
      they have entered into a multi-year agreement that appoints HSW and DNA Chip Research, Inc. (DCR) through MiraiBio as
      Luminex`s sole Japan-based agents.

      HSW and DCR have rights to authorize additional strategic partners in Japan who are expected to utilize the Luminex technology
      for a wide variety of products and services. Luminex will receive royalties based on the products commercialized and services
      performed by these Japanese strategic partners. HSW and DCR also have rights to distribute Luminex instruments and
      consumables in Japan. This agreement complements and expands the previous distribution agreement that Luminex and MiraiBio
      announced last year.

      Under the agreement, MBI has agreed to purchase over $3.0 million of Luminex systems over the next 15 months.

      ``We are thrilled to embark on this close relationship with Luminex. We are ideally situated to represent the Luminex technology in
      Japan,`` stated Leonard Klevan, MBI`s President and CEO. ``The Japanese market represents a major opportunity for the
      introduction of advanced, innovative methods for bioassay development based upon the Luminex technology platform.``

      ``Because the LabMAP technology can be applied to biological tests in every area of the life science industry, it was important
      that Luminex acquire a partner with marketing and technical expertise throughout this field,`` stated Mark Chandler, Luminex`s
      Chairman and CEO. ``Hitachi Software Engineering and its associated companies met this requirement perfectly. We are
      confident that our current customers in Japan will be excited to have the support of such a powerful and well-respected
      company.``

      Luminex`s proprietary open platform LabMAP technology can perform up to 100 assays simultaneously on a single drop of fluid
      with the capability for both medium and high-throughput assay applications. This system combines the use of low-cost
      microsphere-based assays with small lasers, advanced digital signal processors and proprietary software to offer greater speed,
      precision and flexibility over other current bioassay technologies.

      About Luminex Corporation

      Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The
      company`s LabMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as
      diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research. The LabMAP system is sold worldwide and is already in use in leading
      research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or LabMAP can be
      obtained on the Internet at http://www.luminexcorp.com .

      About MiraiBio, Inc.

      MiraiBio, Inc (formerly the Genetic Systems Division of Hitachi Software Engineering America, Ltd.), was spun off as a subsidiary dedicated to serving the life
      sciences market. MiraiBio delivers proven solutions for life science research in fields such as genomics, proteomics, drug discovery, and forensics. The company
      offers products for bioimaging, microarrays, bioinformatics, and spectroscopy. Bioimaging products include fluorescence and CCD-based imaging systems.
      Microarray systems include an automated spotter, and data management software. Next-generation spectroscopy instruments for DNA/RNA/protein measurements
      with full UV/Visible scans expands the product line. A preview of the company and its products can be obtained on the Internet at http://www.miraibio.com .

      About Hitachi Software Engineering, Co., Ltd.

      Hitachi Software Engineering Co., Ltd., (HSW) is a publicly traded company on the First Section of Tokyo Stock Exchange, with net sales of 1.5 billion dollars in
      2000. HSW was established in 1970 as the first software company in The Hitachi Group. Its software products range in application from hand-held computers to
      super-computers, and are widely used by financial institutions, government agencies, utility companies and others. HSW took advantage of its depth of accumulated
      technology know-how, and its reputation for superior quality and reliability when, in 1983, it moved into the life sciences market with the introduction of DNASIS
      software. HSW continues its advance into the life sciences market by offering products for microarrays, and advanced bioinformatics. A preview of the company
      and its products can be obtained on the Internet at http://www.hitachi-sk.co.jp .

      Statements made in this press release that express Luminex`s or management`s intentions, plans, beliefs, expectations or predictions of future events are
      forward-looking statements. The words ``believe,`` ``expect,`` ``intend,`` ``estimate,`` ``anticipate,`` ``will`` and similar expressions are intended to further identify such
      forward-looking statements. It is important to note that the company`s actual results or performance could differ materially from those anticipated or projected in
      such forward-looking statements. Factors that could cause Luminex`s actual results or performance to differ materially include risks and uncertainties relating to
      market demand and acceptance of Luminex`s products, the company`s dependence on strategic partners for development and distribution of products, the
      company`s ability to protect its intellectual property in Japan, competition, Luminex`s ability to scale-up manufacturing operations, potential shortages of components
      and the timing of regulatory approvals, as well as the risks discussed under the heading ``Factors That May Affect Future Results`` in Luminex`s annual report on
      Form 10-K for the year ended December 31, 2000 and Form 10-Q for the quarter ended March 31, 2001, as filed with the Securities and Exchange Commission.
      The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent,
      obligation or undertaking to update or revise such forward-looking statements to reflect any change in Luminex`s expectations with regard thereto or any change in
      events, conditions or circumstances on which any such statements are based.

      Editor`s Note:

      Information on MiraiBio can be found on the Internet at http://www.miraibio.com .

      Information on Hitachi Software Engineering, Ltd. can be found on the Internet at http://www.hitachi-sk.co.jp/English/index.html .

      Information on Luminex and LabMAP(TM) can be found on the Internet at http://www.luminexcorp.com .

      Contacts:
      MiraiBio, Inc.
      (a subsidiary of Hitachi Software Engineering, Co., Ltd.)
      (510) 337-2034
      Leonard Klevan
      President

      CONTACT INFO in JAPAN
      Hitachi Software Engineering, Co., Ltd.
      011-81-45-681-2111
      Masafumi Shimoda
      General Manager
      Life Science Promotion Division

      Luminex Corporation
      (512) 219-8020
      Frank Reeves
      Chief Financial Officer

      SOURCE: Luminex Corporation


      gruss
      tb 2
      Avatar
      schrieb am 01.04.02 23:46:31
      Beitrag Nr. 9 ()
      Luminex Corporation Provides Preliminary First Quarter 2002 ...
      Alle Nachrichten


      01.04. / 23:31



      < zurück <



      > Archiv >


      Luminex Corporation announced today that it expects first quarter 2002 revenue and earnings to be significantly
      below the Company`s earlier guidance as a result of continuing delays in the commercialization timetables of a
      number of its strategic partners. Based on a preliminary analysis of first quarter shipments, revenues currently are
      expected to be in the range of $2.2 to $2.7 million. At this level of revenue, the Company estimates diluted loss
      per share will be in the range of $0.20 to $0.23 for the quarter ended March 31, 2002.

      Commenting on the revised outlook, Mark Chandler, Luminex Chairman and CEO, said, "Our revenues continue to
      be negatively affected by the lengthy and unpredictable sales cycle for the Company`s instruments and
      consumable products. Contributing to the current quarter`s shortfall was a change in the Company`s pricing
      strategy to eliminate end-of-quarter discounting. Similar to a number of companies in hardware- and
      software-based industries, significant sales of the Company`s products have occurred in the last two weeks of the
      quarter. We feel strongly that this change in pricing strategy is vital to the long-term success of the Company. It
      should enhance our margins and spread sales more evenly over the quarter, thereby providing a clearer picture of
      the acceptance of the Luminex technology for management, the investment community and our stockholders."

      Dr. Chandler continued, "We remain extremely optimistic about the market acceptance of the Luminex(R) platform.
      Our limited operating history and reliance on strategic partners to market our products, however, makes
      forecasting quarter to quarter, as well as annual revenue and operating results, extremely difficult. We currently
      expect full-year 2002 revenues to fall below previously announced annual guidance of $35 to $40 million. We will
      be prepared to discuss our financial outlook for the remainder of 2002 in greater detail during our regularly
      scheduled first quarter 2002 earnings conference call to be held later this month."

      Luminex will host a conference call to discuss the preliminary 2002 first quarter financial outlook at 5:00 p.m.
      Eastern Standard Time on April 1, 2002. The call will be available via Web cast live at
      http://www.luminexcorp.com/ . Simply log on to the web at the address above and access the Investor Relations
      link.

      Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with
      applications throughout the life sciences industry. The Company`s xMAP(TM) system is an open-architecture, multi-
      analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse
      as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and
      proteomics research markets. The Company`s xMAP technology is sold worldwide and is already in use in leading
      research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further
      information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com/ .

      Statements made in this press release that express Luminex`s or management`s intentions, plans, beliefs,
      expectations or predictions of future events are forward-looking statements. The words "believe," "expect,"
      "intend," "estimate," "anticipate," "will" and similar expressions are intended to further identify such
      forward-looking statements. It is important to note that the Company`s actual results or performance could differ
      materially from those anticipated or projected in such forward-looking statements. Factors that could cause
      Luminex`s actual results or performance to differ materially include risks and uncertainties relating to fluctuations in
      quarterly results due to a lengthy and unpredictable sales cycle, market demand and acceptance of Luminex`s
      products, the Company`s dependence on strategic partners for development, commercialization and distribution of
      products, competition, Luminex`s ability to scale-up manufacturing operations, potential shortages of components
      and the timing of regulatory approvals, as well as the risks discussed under the heading "Factors That May Affect
      Future Results" in Luminex`s Form 10-K for the year ended December 31, 2001, as filed with the Securities and
      Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of
      the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to update or
      revise such forward-looking statements to reflect any change in Luminex`s expectations with regard thereto or any
      change in events, conditions or circumstances on which any such statements are based.

      Contact: Mark B. Chandler, Ph.D. Chairman & CEO (512) 219-8020

      Luminex Corporation

      © PR Newswire

      gruss
      tb 2


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      -0,42
      -0,94
      +0,22
      -1,79
      +11,83
      +0,85
      +0,95
      +0,13
      +1,55
      0,00
      wer kennt LUMINEX ???